Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy

HIV Clinical Trials

Volumn 9, Issue 6, 2008, Pages 399-406

  Yang, Yong ^a   Yap, Marline ^a   Tha, Naing Oo ^a   Paton, Nicholas I ^a,b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Antiretroviral treatment; Facial lipoatrophy; HIV; Laser scanning

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RELIABILITY;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; DRUG THERAPY, COMBINATION; FACE; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LASERS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; YOUNG ADULT;

EID: 62649129757     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0906-399     Document Type: Article

References (27)

1. Echavez M, Horstman W. Relationship between lipoatrophy and quality of life. AIDS Read. 2005;15:369-375.
2. Talmor M, Hoffman LA, LaTrenta GS. Facial atrophy in HIV-related fat redistribution syndrome: Anatomic evaluation and surgical reconstruction. Ann Plast Surg. 2002;49:11-17; discussion 117-118.
3. Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM. Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Saf. 2001,24:157-166.
4. Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect. 2003; 79:137-141.
5. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6(Suppl 2):1-61.
6. John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
7. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS. 2004;18:1029-1036.
8. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003;33:22-28.
9. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS. 2003; 17:2471-2477.
10. Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-87.
11. Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina JM. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:393-398.
12. Jones DH, Carruthers A, Orentreich D, Brody HJ, Lai MY, Azen S, Van Dyke GS. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: An open pilot trial. Dermatol Surg. 2004;30:1279-1286.
13. Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antiviral Ther. 2006;11:179-186.
14. Wilson I, Snape L, Fright R, Nixon M. An investigation of laser scanning techniques for quantifying changes in facial soft-tissue volume. N Z Dent J 1997;93:110-113.
15. Ferrario VF, Sforza C, Serrao G, Ciusa V, Dellavia C. Growth and aging of facial soft tissues:. A computerized three-dimensional mesh diagram analysis. Clin Anat. 2003;16: 420-433.
16. Soncul M, Bamber MA. The reproducibility of the head position for a laser scan using a novel morphometric analysis for orthognathic surgery. Int J Oral Maxillofac Surg. 2000;29:86-90.
17. Wilks RJ. An optical system for measuring surface shapes for radiotherapy planning. Br J Radiol. 1993;66:351-359.
18. Paton NI, Yang Y, Sitoh YY, Oo Tha N. Validation of three-dimensional laser scanning for the assessment of facial fat changes. HIV Med. 2007;8:498-503.
19. Carr A, Emery S, Law M, Puls R, Lundgrea-JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet. 2003;361: 726-735.
20. Yang Y, Paton NI. Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: Evaluation of accuracy and reproducibility. HIV Med. 2005;6:321-325.
21. Paton NI, Yang Y, Tha NO, Sitoh YY. Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging. HIV Clin Trials. 2007;8:227-234.
22. Benn P, Sauret V, Cartledge J, Ruff C, Sabin CA, Moyle G, et al. Improvements in facial lipoatrophy at 48 weeks following substitution of a thymidine analogue with tenofovir or abacavir: A randomized, open-label study in people with lipoatrophy and virological suppression on HAART. In: Program and abstracts of the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; November 13-16, 2005; Dublin. Abstract 8:
23. Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther. 2006;11:179-186.
24. Yang Y, Wilder-Smith A, Panchalingam A, Tha NO, Paton NI. Changes in body fat measured by DEXA in patients taking different formulations of stavudine. HIV Clin Trials. 2005;6:337-343.
25. Yang Y, Sitoh YY, Oo Tha N. Paton NI. Facial fat volume in HIV-infected patients with lipoatrophy. Antivir Ther. 2005; 10:575-581.
26. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg. 2007;101:793-798.
27. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Orespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139-147.